Sustained-release pramipexole in the treatment of Parkinson’s disease by Natalia Vladimirovna Fedorova

Subjects: “…immediate- and extended-release pramipexole…”
Get full text

Parkinson's disease fatigability and its correction with the dopamine receptor agonist pramipexole by M. R. Nodel

Subjects: Get full text

Capacities of the dopamine receptor agonist pramipexole in the treatment of patients with Parkinson’s disease by S N Illarioshkin

Subjects: Get full text

Pharmacoeconomic evaluation of pramipexole extended release monotherapy in early Parkinson’s disease by D. Yu. Belousov, E. V. Afanasyeva

Subjects: Get full text

USE OF EXTENDED-RELEASE PRAMIPEXOLE IN EARLY-STAGE PARKINSON’S DISEASE: DESCRIPTION OF A CLINICAL CASE by N. V. Fedorova, Ye. N. Gubanova

Subjects: Get full text

USE OF EXTENDED-RELEASE PRAMIPEXOLE IN EARLY-STAGE PARKINSON’S DISEASE: DESCRIPTION OF A CLINICAL CASE by N. V. Fedorova, Ye. N. Gubanova

Subjects: Get full text

Sleep disorders in Parkinson's disease by M. R. Nodel

Subjects: Get full text

Apathy in Parkinson's disease patients by M. R. Nodel

Subjects: Get full text

Current therapy for Parkinson's disease by A. V. Obukhova

“…A novel extended-release formulation of pramipexole is considered separately. Both immediate- and extended-release pramipexole formulations contain the same active ingredient and have the same dopamine-receptor interaction profile, but differ in the tablet release rate of the active ingredient. …”
Get full text

Profile and frequency of antiparkinsonian drugs adverse reactions: a systematic review and meta-analysis by A. A. Tappakhov, T. E. Popova, A. I. Vasilev, T. G. Govorova, Yu. I. Khabarova, K. A. Timofeeva, N. A. Schnaider

“…Dizziness was more common with pramipexole and ropinirole than with levodopa (OR=1.82; 95% CI: 1.21–2.74 and OR=1.65; 95% CI: 1.11–2.44 respectively). …”
Get full text

Family case of aromatic L-amino acid decarboxylase deficiency by O. B. Kondakova, K. A. Kazakova, A. A. Lyalina, N. V. Lapshina, A. A. Pushkov, N. N. Mazanova, Yu. I. Davydova, D. I. Grebenkin, I. V. Kanivets, K. V. Savostyanov

“…The patient’s condition was improved by using of combination therapy with pyridoxal‑5‑phosphate, pramipexole and selegiline. Significant positive dynamics was achieved on pyridoxal‑5‑phosphate therapy for the first time.…”
Get full text